蛋白激酶C对心脏疾病的调节机制及其抑制药的治疗作用

焦雅丽, 韩光, 崔丹

武警医学 ›› 2020, Vol. 31 ›› Issue (7) : 621-624.

PDF(895 KB)
PDF(895 KB)
武警医学 ›› 2020, Vol. 31 ›› Issue (7) : 621-624.
综述

蛋白激酶C对心脏疾病的调节机制及其抑制药的治疗作用

  • 焦雅丽, 韩光 综述, 崔丹 审校
作者信息 +
文章历史 +

引用本文

导出引用
焦雅丽, 韩光, 崔丹. 蛋白激酶C对心脏疾病的调节机制及其抑制药的治疗作用[J]. 武警医学. 2020, 31(7): 621-624
中图分类号: R541   

参考文献

[1] Benjamin E J, Virani S S, Callaway C W, et al. Heart disease and stroke statistics-2018 update: a report from the american heart association[J]. Circulation, 2018, 137(12): e67-e492.
[2] Makhoul S, Dorschel S, Gambaryan S, et al. Feedback regulation of syk by protein kinase c in human platelets[J]. Int J Mol Sci, 2019, 21(1):176-182.
[3] Schunke K J, Walton C B, Veal D R, et al. Protein kinase C binding protein 1 inhibits hypoxia-inducible factor-1 in the heart[J]. Cardiovasc Res, 2019, 115(8): 1332-1342.
[4] Singh R K, Kumar S, Tomar M S, et al. Classical protein kinase C: a novel kinase target in breast cancer[J]. Clin Transl Oncol, 2019, 21(3): 259-267.
[5] 许 忠,何晓飞,徐 凯,等.蛋白激酶在大鼠缺血及再灌注脑损伤中的调节作用[J].武警医学,2018,29(03):250-252,256.
[6] Sharp T E , Kubo H, Berretta R M, et al. Protein kinase C inhibition with ruboxistaurin increases contractility and reduces heart size in a swine model of heart failure with reduced ejection fraction[J]. JACC Basic Transl Sci, 2017, 2(6): 669-683.
[7] Lange S, Gehmlich K, Lun A S, et al. MLP and CARP are linked to chronic PKC alpha signalling in dilated cardiomyopathy[J]. Nat Commun, 2016, 7(6): 12120.
[8] Braun C, Parks X X, Qudsi H, et al. PKC betaII specifically regulates KCNQ1/KCNE1 channel membrane localization[J]. J Mol Cell Cardiol, 2019: 283-290.
[9] Smyrnias I, Goodwin N, Wachten D, et al. Contractile responses to endothelin-1 are regulated by PKC phosphorylation of cardiac myosin binding protein-C in rat ventricular myocytes[J]. J Mol Cell Cardiol, 2018, 117: 1-18.
[10] Lee S J, Kim S J, Lee H S, et al. PKC delta Mediates NF-kappa B inflammatory response and downregulates SIRT1 Expression in liver fibrosis[J]. Int J Mol Sci, 2019, 20(18): 4607.
[11] Song M, Matkovich S J, Zhang Y, et al. Combined cardiomyocyte PKCdelta and PKC epsilon gene deletion uncovers their central role in restraining developmental and reactive heart growth[J]. Sci Signal, 2015, 8(373): 39.
[12] Diaz J L, Macias L A, Alcala V F, et al. Redox signaling in ischemic postconditioning protection involves PKCepsilon and Erk1/2 pathways and converges indirectly in Nrf2 activation[J]. Cell Signal, 2019, 64(10): 109417.
[13] Liu C, Li H, Zheng H, et al. CaSR activates PKC delta to induce cardiomyocyte apoptosis via ER stressassociated apoptotic pathways during ischemia/reperfusion[J]. Int J Mol Med, 2019, 44(3): 1117-1126.
[14] Shou X, Wang B, Zhou R, et al. Baicalin suppresses hypoxia-reoxygenation-induced arterial endothelial cell apoptosis via suppressing PKCdelta/p53 signaling[J]. Med Sci Monit, 2017, 23: 6057-6063.
[15] Lu Z, Ballou L M, Jiang Y P, et al. Restoration of defective L-type Ca2+ current in cardiac myocytes of type 2 diabetic db/db mice by Akt and PKC-iota[J]. J Cardiovasc Pharmacol, 2011, 58(4): 439-445.
[16] Habets D D, Luiken J J, Ouwens M, et al. Involvement of atypical protein kinase C in the regulation of cardiac glucose and long-chain fatty acid uptake[J]. Front Physiol, 2012, 3: 361.
[17] Ladage D, Tilemann L, Ishikawa K, et al. Inhibition of PKC alpha/beta with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury[J]. Circ Res, 2011, 109(12): 1396-1400.
[18] Wei L, Sun D, Yin Z, et al. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats[J]. Apoptosis, 2010, 15(4): 488-498.
[19] Zhong C, Wu Y, Chang H, et al. Effect of PKC inhibitor on experimental autoimmune myocarditis in Lewis rats[J]. Oncotarget, 2017, 8(33): 54187-54198.
[20] Brennan S, Chen S, Makwana S, et al. A novel form of glycolytic metabolism-dependent cardioprotection revealed by PKC alpha and beta inhibition[J]. J Physiol, 2019, 597(17): 4481-4501.
[21] Kunikawa S, Tanaka A, Takasuna Y, et al. A novel 2,4-diaminopyrimidine derivative as selective inhibitor of protein kinase C theta prevents allograft rejection in a rat heart transplant model[J]. Bioorg Med Chem, 2018, 26(20): 5499-5509.
[22] Li Z, Abdullah C S, Jin Z Q .Inhibition of PKC-theta preserves cardiac function and reduces fibrosis in streptozotocin-induced diabetic cardiomyopathy[J]. Br J Pharmacol, 2014, 171(11): 2913-2924.
[23] Fang Y H, Joo D J, Lim B J, et al. The effects of AEB071 (sotrastaurin) with tacrolimus on rat heterotopic cardiac allograft rejection and survival[J]. J Surg Res, 2011, 171(1): e133-137.
[24] Kim E C, Lee M J, Shin S Y, et al. Phorbol 12-myristate 13-acetate enhances long-term potentiation in the hippocampus through activation of protein kinase cdelta and epsilon[J]. Korean J Physiol Pharmacol, 2013, 17(1): 51-56.
[25] Miyaji Y, Walter S, Chen L, et al. Distribution of KAI-9803, a novel delta-protein kinase C inhibitor, after intravenous administration to rats[J]. Drug Metab Dispos, 2011, 39(10): 1946-1953.
[26] Lincoff A M, Roe M, Aylward P, et al. Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the protection ami randomized Controlled Trial[J]. Eur Heart J, 2014, 35(37): 2516-2523.
[27] Kim H K, Cho S W, Heo H J, et al. A Novel atypical PKC-Iota inhibitor, echinochrome a, enhances cardiomyocyte differentiation from mouse embryonic stem cells[J]. Mar Drugs, 2018, 16(6):1-14.
[28] 魏碧玉,刘永哲,常宇飞,等.CrSO2联合Pcv-aCO2对发绀型婴幼儿心脏手术后ICU停留时间的预测意义[J].武警医学,2019,30(11):952-955.
[29] Ravichandran V S, Patel H J, Pagani F D, et al. Cardiac contractile dysfunction and protein kinase C-mediated myofilament phosphorylation in disease and aging[J]. J Gen Physiol, 2019, 151(9): 1070-1080.

PDF(895 KB)

Accesses

Citation

Detail

段落导航
相关文章

/